Evidence map›Paper›PMID 35397508›Full record

Trial reportBMC cancer2022

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.

Anthony B El-Khoueiry, Tim Meyer, Ann-Lii Cheng, Lorenza Rimassa, Suvajit Sen, Steven Milwee, Robin Kate Kelley, Ghassan K Abou-Alfa

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01908426 (A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib), which is not on this map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01908426 phase3completednot on this map

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

TypeinterventionalSponsorExelixisRan2013 to 2021Enrolled707ConditionsHepatocellular CarcinomaArmsCabozantinib tablets, Placebo tablets
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Impact of Child Pugh B Stage for the Treatment of Advanced HCC.Journal of hepatocellular carcinoma · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 4 countries.

Anthony B El-KhoueiryUSC Norris Comprehensive Cancer Center, Los Angeles, CA, USA. elkhouei@med.usc.edu.
Tim MeyerRoyal Free Hospital, University College London, London, UK.
Ann-Lii ChengNational Taiwan University Hospital, Taipei, Taiwan.
Lorenza RimassaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Suvajit SenExelixis, Inc, Alameda, CA, USA.
Steven MilweeExelixis, Inc, Alameda, CA, USA.
Robin Kate KelleyUCSF Helen Diller Family Comprehensive Cancer Center, CA, San Francisco, USA.
Ghassan K Abou-AlfaMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Exelixis (United States) · USHumanitas University · ITMemorial Sloan Kettering Cancer Center · USNational Taiwan University Hospital · TWUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity College London · GBUSC Norris Comprehensive Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundPatients with hepatocellular carcinoma (HCC) and Child-Pugh B liver cirrhosis have poor prognosis and are underrepresented in clinical trials. The CELESTIAL trial, in which cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with HCC and Child-Pugh A liver cirrhosis at baseline, was evaluated for outcomes in patients who had Child-Pugh B cirrhosis at Week 8.

methodsThis was a retrospective analysis of adult patients with previously treated advanced HCC. Child-Pugh B status was assessed by the investigator. Patients were randomised 2:1 to cabozantinib (60 mg once daily) or placebo.

resultsFifty-one patients receiving cabozantinib and 22 receiving placebo had Child-Pugh B cirrhosis at Week 8. Safety and tolerability of cabozantinib for the Child-Pugh B subgroup were consistent with the overall population. For cabozantinib- versus placebo-treated patients, median OS from randomisation was 8.5 versus 3.8 months (HR 0.32, 95% CI 0.18-0.58), median PFS was 3.7 versus 1.9 months (HR 0.44, 95% CI 0.25-0.76), and best response was stable disease in 57% versus 23% of patients.

conclusionsThese encouraging results with cabozantinib support the initiation of prospective studies in patients with advanced HCC and Child-Pugh B liver function. CLINICAL

trial registrationNCT01908426.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsAdultAnilidesHumansLiver CirrhosisProspective StudiesPyridinesRetrospective StudiesAnilidesAntineoplastic AgentscabozantinibPyridinesCabozantinibChild–Pugh BHepatocellular carcinoma

Identifiers

PMID35397508
PMCPMC8994237
OpenAlexW4223425949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.